← boardnext 2027-04-25
ORMP
Oramed, Ltd.distress 0/10 · well-funded / low risk$3.98-1%today-20% from 52w high
Lead: Type 2 Diabetes Mellitus · est. market ~$70B (approx, global)
Revenue
pre-revenue
Liquidity
$36M
Runway
4.2 yrs
Shares 1y
0%
Price & events
+20.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-1.6%
1W
-4.4%
1M
+3.8%
3M
+17.6%
6M
+85.9%
1Y
+62.5%
2Y
-70.3%
5Y
-1.7%
All
Overview
- Market Cap
- $163.09M
- Volume
- 10.02K
- 52 Week Range
- $2.06 – $5.00
- Total Shares
- 40.93M
- Float Shares
- 31.59M
- Short %
- 2.54%
- % Held by Insiders
- 17.93%
- % Held by Institutions
- 31.65%
- RVOL
- 0.02x
- Beta
- 1.20
Pipeline stages · 1 programs
ORMD-0801 8 mg, ORMD-0801 16 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-04-25 Estimated 50% readout ~2027-07-09 | Phase 3 | ORMD-0801 8 mg, ORMD-0801 16 mg | Type 2 Diabetes Mellitus | — | not yet recruiting |
Catalyst news & presentations · 8
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-01-12partnershipOramed enters Notes Purchase Agreement to invest $9M in Lifeward via senior secured convertible notes.SEC 8-K
- 2026-01-12partnershipOramed enters Share Purchase Agreement to sell Oratech to Lifeward for shares, warrants, and revenue payments.SEC 8-K
- 2025-12-30partnershipScilex repurchased remaining warrants from Oramed for $14 million plus $750k option fee, completing $28.5M total payment.SEC 8-K
- 2025-10-23withdrawalJoint venture with HTIT terminated due to partner's inability to satisfy closing conditionsSEC 8-K
- 2025-09-30partnershipFirst tranche of warrant repurchase completed for $13,000,000.SEC 8-K
- 2025-04-28partnershipOramed purchased 14.1M Alpha Tau shares and entered a three-year IR/PR services agreement.SEC 8-K
- 2025-02-07partnershipEntered into Supplemental Agreement to amend joint venture with HTITSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $6 (+57% upside) · 1 analysts
- 2024-09-09HC Wainwright & Co.Neutral
Competitors — Type 2 Diabetes Mellitus
Recent news
- 2026-07-17Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback - Ad-hoc-news.de
- 2026-07-16Oramed Pharmaceuticals Inc. Net Worth (2026) - GuruFocus
- 2026-07-09Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
- 2026-07-08Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects - Ad-hoc-news.de
- 2026-07-04Price to book forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
- 2026-07-02Oramed Pharmaceuticals Incorporated Financial Disclosures & SEC Filings - TradingView
- 2026-07-02ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares - Stock Titan
- 2026-07-01Form 144 ORAMED PHARMACEUTICALS INC. For: 1 July By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.